Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
Abstract Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen increases patients’ susceptibility to myocardial injury, reduction in left ventricular ejection fraction and complications associated with heart failure. There is currently no standardized, minimally...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-87209-8 |
| _version_ | 1819039925483339776 |
|---|---|
| author | Hari Vishal Lakhani Sneha S. Pillai Mishghan Zehra Benjamin Dao Maria Tria Tirona Ellen Thompson Komal Sodhi |
| author_facet | Hari Vishal Lakhani Sneha S. Pillai Mishghan Zehra Benjamin Dao Maria Tria Tirona Ellen Thompson Komal Sodhi |
| author_sort | Hari Vishal Lakhani |
| collection | DOAJ |
| description | Abstract Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen increases patients’ susceptibility to myocardial injury, reduction in left ventricular ejection fraction and complications associated with heart failure. There is currently no standardized, minimally invasive, cost effective and clinically verified procedure to monitor cardiotoxicity post-anthracycline therapy initiation, and to detect early onset of irreversible cardiovascular complications. This study aims to create a panel of novel biomarkers and circulating miRNAs associated with cardiotoxicity, further assessing their correlation with cardiac injury specific markers, troponin I and T, and demonstrate the development of cardiac dysfunction in breast cancer patients. Blood obtained from West Virginian females clinically diagnosed with breast cancer and receiving anthracyclines showed upregulated level of biomarkers and circulating miRNAs after 3 and 6 months of chemotherapy initiation with increased levels of cardiac troponin I and T. These biomarkers and miRNAs significantly correlated with elevated troponins. Following 6 months of anthracycline-regimens, 23% of the patient population showed cardiotoxicity with reduced left ventricular ejection fraction. Our results support the clinical application of plasma biomarkers and circulating miRNAs to develop a panel for early diagnosis of chemotherapy related cardiac dysfunction which will enable early detection of disease progression and management of irreversible cardiac damage. |
| first_indexed | 2024-12-21T09:00:57Z |
| format | Article |
| id | doaj.art-43f4b838effc46a2b3b54fd017e269af |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-21T09:00:57Z |
| publishDate | 2021-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-43f4b838effc46a2b3b54fd017e269af2022-12-21T19:09:28ZengNature PortfolioScientific Reports2045-23222021-04-0111111110.1038/s41598-021-87209-8Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancerHari Vishal Lakhani0Sneha S. Pillai1Mishghan Zehra2Benjamin Dao3Maria Tria Tirona4Ellen Thompson5Komal Sodhi6Departments of Surgery and Biomedical Sciences, Marshall University Joan C. Edwards School of MedicineDepartments of Surgery and Biomedical Sciences, Marshall University Joan C. Edwards School of MedicineDepartments of Surgery and Biomedical Sciences, Marshall University Joan C. Edwards School of MedicineDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C. Edwards School of MedicineDepartment of Oncology, Edwards Comprehensive Cancer Center, Marshall University Joan C. Edwards School of MedicineDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C. Edwards School of MedicineDepartments of Surgery and Biomedical Sciences, Marshall University Joan C. Edwards School of MedicineAbstract Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen increases patients’ susceptibility to myocardial injury, reduction in left ventricular ejection fraction and complications associated with heart failure. There is currently no standardized, minimally invasive, cost effective and clinically verified procedure to monitor cardiotoxicity post-anthracycline therapy initiation, and to detect early onset of irreversible cardiovascular complications. This study aims to create a panel of novel biomarkers and circulating miRNAs associated with cardiotoxicity, further assessing their correlation with cardiac injury specific markers, troponin I and T, and demonstrate the development of cardiac dysfunction in breast cancer patients. Blood obtained from West Virginian females clinically diagnosed with breast cancer and receiving anthracyclines showed upregulated level of biomarkers and circulating miRNAs after 3 and 6 months of chemotherapy initiation with increased levels of cardiac troponin I and T. These biomarkers and miRNAs significantly correlated with elevated troponins. Following 6 months of anthracycline-regimens, 23% of the patient population showed cardiotoxicity with reduced left ventricular ejection fraction. Our results support the clinical application of plasma biomarkers and circulating miRNAs to develop a panel for early diagnosis of chemotherapy related cardiac dysfunction which will enable early detection of disease progression and management of irreversible cardiac damage.https://doi.org/10.1038/s41598-021-87209-8 |
| spellingShingle | Hari Vishal Lakhani Sneha S. Pillai Mishghan Zehra Benjamin Dao Maria Tria Tirona Ellen Thompson Komal Sodhi Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer Scientific Reports |
| title | Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer |
| title_full | Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer |
| title_fullStr | Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer |
| title_full_unstemmed | Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer |
| title_short | Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer |
| title_sort | detecting early onset of anthracyclines induced cardiotoxicity using a novel panel of biomarkers in west virginian population with breast cancer |
| url | https://doi.org/10.1038/s41598-021-87209-8 |
| work_keys_str_mv | AT harivishallakhani detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT snehaspillai detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT mishghanzehra detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT benjamindao detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT mariatriatirona detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT ellenthompson detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT komalsodhi detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer |